JNCCN 360 - B-Cell Lymphomas - Available Clinical Trials

Editor:

Leo I. Gordon, MD, FACP

Advertisement

Advertisement

Available Clinical Trials

A Phase I/II Study of Copanlisib Plus Venetoclax for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-Cell Lymphoma

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

Phase II Study of Dose-Reduced Consolidation Radiation Therapy in Patients with Diffuse Large B-cell Lymphoma

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-Cell Non-Hodgkin Lymphoma

Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies

Sections

NCCN Resources

Copyright © 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.